

T-CELL-DEPENDENT ANTIBODY RESPONSE (TDAR)

OVERVIEW

The immune system has been identified as a target organ for adverse effects caused by test material administration. Because of this, the T-Cell-Dependent Antibody Response (TDAR) assay is used to assess potential immunotoxicity and to determine the impact of a test material on the immune response at the preclinical stage of drug discovery. This assay is the gold-standard for studying these effects due to the requirement of multiple immune functions and cell types to generate an antibody response including antigen uptake and presentation, CD4 T cell help, B cell activation and antibody production.

Biomere has validated multiple TDAR models including non-human primates and rodent models.

TDAR ASSAY ANIMAL MODELS AVAILABLE

Non-Human Primates

- KLH-peptide immunization in cynomolgus macaques


Rodents

- KLH-peptide immunization in C57BL/6 female mice
- OVA-peptide in alhydrogel immunizations in C57BL/6 female mice

TDAR ASSAY READOUTS


- IgG and IgM serum levels by ELISA
- Immune response analysis by flow cytometry
- Hematology analysis by complete blood count (CBC)

MOUSE T-CELL-DEPENDENT ANTIBODY RESPONSE (TDAR)



Female C57BL/6 mice from JAX were treated with either vehicle or anti-CD154 mAb intraperitoneally (IP) on Day -1. On Day 0, mice were given NP:KLH IP. Serum was collected from mice on Day -1, 7, and 14 and (A) anti-NP IgM and (B) anti-NP IgG ELISAs were performed.

NHP T-CELL-DEPENDENT ANTIBODY RESPONSE




Naive male and female cynomolgus macaques of Chinese origin were treated with vehicle or anti-CD154 mAb IV on Day 0, 14, and 28. On Day 3 and 31, NHPs received KLH intramuscularly (IM). Serum was collected from animals twice weekly through Day 56 and (A) anti-KLH IgM and (B) anti-KLH IgG ELISAs were performed on serum samples. (C-I) Flow cytometry was performed on blood samples on Day 49. Frequency of (C) CD4⁺ T_H cells, (D) IFN γ ⁺ T_H cells, and (E) TNF α ⁺ T_H cells. Frequency of (F) CD20⁺ B cells, (G) Naive B Cells, (H) Germinal Center B Cells, and (I) Memory B Cells.

SUMMARY

Significant decreases were observed in IgM and IgG antibodies generated in both the mouse and NHP TDAR assays in immune suppressive treatment (α -CD40L) compared to vehicle control. A proportional decrease in germinal center B cells compared to other B cell groups, as well as a decrease in B cells as a total population in α -CD40L versus control were observed. Decreases in the proportion of CD4⁺ T_H cells were also observed in α -CD40L treated versus control, with a decrease in the proportion of IFN γ ⁺ T_H cells. From these results, we can see α -CD40L was able to suppress the generation of antibodies against the target antigen and impacted the T_H cell and germinal center B cell response.

IT'S PERSONAL.

Driven to expedite your journey.



"The FDA recommends that evaluation of potential adverse events on the immune response be incorporated into standard drug development. The TDAR assay is the gold standard for studying the effects of a test material on multiple aspects of the immune response. Biomere effected the validation of multiple TDAR animal models and developed readouts for these assays supporting our clients' needs."

- Elizabeth O., Scientist